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Abstract
The accumulation of the scrapie prion protein PrPSc, a misfolded conformer of the cellular
prion protein PrPC, is a crucial feature of prion diseases. In the central nervous system, this
process is accompanied by conspicuous microglia activation. The NLRP3 inflammasome is
a multi-molecular complex which can sense heterogeneous pathogen-associated molecu-
lar patterns and culminates in the activation of caspase 1 and release of IL 1β. The NLRP3
inflammasome was reported to be essential for IL 1β release after in vitro exposure to the
amyloidogenic peptide PrP106-126 and to recombinant PrP fibrils. We therefore studied the
role of the NLRP3 inflammasome in a mouse model of prion infection. Upon intracerebral
inoculation with scrapie prions (strain RML), mice lacking NLRP3 (Nlrp3-/-) or the inflamma-
some adaptor protein ASC (Pycard-/-) succumbed to scrapie with attack rates and incuba-
tion times similar to wild-type mice, and developed the classic histologic and biochemical
features of prion diseases. Genetic ablation of NLRP3 or ASC did not significantly impact
on brain levels of IL 1β at the terminal stage of disease. Our results exclude a significant
role for NLRP3 and ASC in prion pathogenesis and invalidate their claimed potential as ther-
apeutic target against prion diseases.
Introduction
The transition from the cellular prion protein (PrPC) to its misfolded, amyloidogenic conform-
er (PrPSc), is crucial to the generation of infectious prions [1], and is the central feature of a
class of invariably fatal, transmissible neurodegenerative disorders termed prion diseases [2].
The adaptive immune system lacks the ability to mount anti-prion immune responses [3], pos-
sibly due to similar immunogenicity between PrPC and PrPSc and, consequently, to immune
tolerance. Conversely, peripherally acquired prions often hijack components of the immune
system to replicate in lymphoid tissues before invading the central nervous system [4].
In the central nervous system (CNS), prion diseases are accompanied by microglia activa-
tion [5–7]. This activation may have beneficial effects, since microglial engulfment of cerebral
apoptotic bodies is an important mechanism of prion clearance [8]. However, there is little un-
derstanding of the role of the innate immune system against prions [9], and in particular of the
mechanisms by which prions activate microglial cells.
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Toll-like receptors (TLRs), key membrane-bound molecules for the recognition of invading
microorganisms, play a limited defensive role in prion diseases [10–12]. In addition to TLRs,
the innate immune system can detect pathogen- or danger-associated molecular patterns
(PAMPs or DAMPs, respectively) through different cytoplasmic proteins, of which the best
characterized are the nucleotide-binding oligomerization-domain protein-like receptors
(NLRs). Among NLRs, NLRP3 (also termed NALP3 or cryopyrin) can sense a plethora of
structurally and chemically heterogeneous PAMPs and DAMPs [13–15], including amyloid β
in models of Alzheimer’s disease [16,17]. Upon activation, NLRP3 enables the formation of a
multi-protein complex named NLRP3 inflammasome, which involves the polymerization of
the adaptor protein ASC and culminates in the activation of caspase-1 and in the proteolytic
processing and subsequent secretion of IL-1β and IL-18 [18–20].
Using in vitromodels based on macrophage/microglia cell lines or primary murine micro-
glia, the NLRP3 inflammasome was found to be essential for IL-1β release upon exposure to ag-
gregates of the PrPC-derived PrP106–126 amyloidogenic neurotoxic peptide [21,22] or in vitro
fibrillized recombinant PrP [23]. However, whether the NLRP3 inflammasome can sense bona
fide prions and significantly impact on prion pathogenesis is presently unknown. Here we set
out to investigate the role of the NLRP3 inflammasome in prion disease in vivo.
Materials and Methods
Ethical statements
Animal care and experimental protocols were all performed in compliance with the Swiss Ani-
mal Protection Law and with the “Swiss Ethical Principles and Guidelines for Experiments on
Animals”, under the approval of the Veterinary office of the Canton Zurich (animal permits
200/2007, 130/2008, 41/2012, 90/2013). Prion inoculations were performed under methoxy-
fluorane anesthesia. All efforts were made to minimize animal discomfort and suffering.
Database search. Cell-specific patterns of gene expression in mouse brains were derived
from RNA sequencing of the transcriptome and splicing database of glia, neurons and vascular
cells of the cerebral cortex [24], available through the following website: http://web.stanford.
edu/group/barres_lab/brain_rnaseq.html.
Microarray-based dynamic gene expression profiles during prion disease development in
different combinations of mouse strains and prion strains were obtained through the Prion
Disease DataBase (PDDB) [25,26], through the following website: http://prion.systemsbiology.
net/page/Welcome/display.
Mice
NLRP3-deficicent mice (C57BL/6-Nlrp3tm1Tsc) [27] and ASC-deficient mice (B6.129-
Pycardtm1Vmd) [28], both on a C57BL/6 background, were kindly provided by Prof. Jurg
Tschopp and C57BL/6 mice were purchased from Harlan, Nederland. PrPC-deficient mice on a
C57BL/6 background (B6.129-Prnptm1Cwe)[29,30] were maintained in house. Mice were kept in
a conventional hygienic grade facility, housed in groups of 3–10 in conventional type II and
type III cages, under a 12 h light/12 h dark cycle (from 7 am to 7 pm) at 22±1°C, with unrestrict-
ed access to sterilized food (Kliba No. 3340, Provimi Kliba, Kaiseraugst, Switzerland) and water.
Genotyping
Tissue biopsies were digested in 10 mM Tris pH 9, 50 mM KCl, 0.5% Tween20, 0.5% NP40, 0.1
mg/mL proteinase K (Roche) and 1 µL of crude digest was employed as template for a PCR re-
action using the Red Taq ReadyMix PCR reaction Mix (Sigma) on a GeneAmp PCR System
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9700 (Applied Biosystems). For the Nlrp3tm1Tsc allele, 0.33 μM of each of the following primers
were used (5’!3’): AAG TCG TGC TGC TTC ATG T, TCA AGC TAA GAG AAC TTT CTG
and ACA CTC GTC ATC TTC AGC A. For the Pycardtm1Vmd allele, 0.33 μM of each of the fol-
lowing primers were used (5’!3’): CTA GTT TGC TGG GGA AAG AAC, CTA AGC ACA
GTC ATT GTG AGC TCC and AAG ACA ATA GCA GGC ATG CTG G. For both PCR reac-
tions, amplification was performed using the following conditions: 5 min at 94°C; 40 cycles of
30 sec at 94°C, 30 sec at 59°C and 40 sec at 72°C; 5 min at 72°C.
Prion inoculations
Mice were injected in the right hemisphere with 30 μl of RML6 (passage 6 of Rocky Mountain
Laboratory strain mouse-adapted scrapie prions) containing 30µg, 90 ng, 30 ng or 9 ng total
protein. Previous titration experiments performed with wild-type CD1 mice showed that the
infectivity titer of the RML6 inoculum is Log LD50 g-1: 9.3 +/- 0.9 [31]. Control inoculations
were performed using 30 µl of non-infectious brain homogenate from CD-1 mice containing
30 µg or 90 ng of total protein.
After inoculation, mice were initially monitored three times per week. After clinical onset,
mice were daily monitored and sacrificed in the presence of clear signs of terminal prion dis-
ease by cervical dislocation. One Pycard-/- mouse inoculated with 90 ng of prions did not devel-
op any sign of prion disease up to 500 days post inoculation, possibly reflecting technical
problems with the inoculation, and was exclude from the survival analysis.
Western blotting
Twenty percent (w/vol) tissue homogenates were prepared in 0.25 M sucrose in PBS using a Ribo-
lyzer (Bio-Rad). Total protein concentration was measured with the BCA Protein Assay (Pierce),
according to the manufacturer’s instructions. For the detection of partially PK-resistant PrP, pro-
teins were digested with PK (Roche) at a final concentration of 25 µg/ml. Protein homogenates in
NuPAGE LDS sample buffer (Invitrogen) containing β-mercaptoethanol as reducing agent were
separated on a NuPAGE 12% Bis-Tris (Invitrogen) using the NuPAGEGel Electrophoresis Sys-
tem (Invitrogen) and transferred onto a Protran Nitrocellulose Transfer Membrane (Whatman)
using theWet/Tank Blotting System (Bio-Rad), according to the manufacturers’ instructions. An-
tibodies used were POM1 (200 ng ml–1 [32]) as primary and HRP-conjugated goat anti-mouse
IgG (H+L) (1:17000 dilution, from Invitrogen) as secondary. Blots were developed using HRP
substrate (ECL, Pierce) and visualized using the Versadoc 3000 imaging system (Bio-Rad).
ELISA
PrPC was quantified in brain tissue homogenate by POM1/POM2 sandwich ELISA as previ-
ously described [32]. IL-1β was quantified in brain tissue homogenate using the Mouse IL-1β
ELISA kit (eBioscience) according to manufacturer’s instructions.
Histology and immunohistochemistry
Stainings were performed on 2 µm sections from formalin fixed, formic acid treated, paraffin
embedded tissues. After deparaffinization through graded alcohols, heat-induced antigen re-
trieval was performed in EDTA-based buffer CC1 and stainings were performed on a NEXES
immunohistochemistry robot (Ventana instruments) using the following antibodies: Iba1
(1:1000, Wako); GFAP (1:13000, Dako); SAF84 (1:200, SPI bio). Only for the latter staining,
antibody incubation was preceded by incubation with protease 2 (Ventana). Immunoreactivity
was visualized using an IVIEW DAB Detection Kit (Ventana). Haematoxylin and eosin
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staining was performed according to standard procedures. Slides were scanned with NanoZoo-
mer and images were visualized using the NanoZoomer Digital Pathology System (NDPview,
Hamamatsu Photonics).
Statistical analysis
Statistical significance was assessed using GraphPad Prism software with One-way ANOVA
and Bonferroni’s multiple comparison post-test, or unpaired Student’s t-test, as appropriate.
Kaplan-Meier method was employed to analyse survival times and comparison between geno-
types was made with the log-rank test. Alpha level was set at 0.05.
For each statistical analysis, the statistical test, p-value, and the group size are indicated in
the corresponding figure legends.
Results
Levels of NLRP3 inflammasome-related transcripts during prion disease
We first investigated the pattern of cellular expression of NLRP3 inflammasome components
within the mouse brain. For this purpose, we took advantage of the recently published RNA-
sequencing-based transcriptome database for mouse brain cortex cells [24]. Transcripts of
Nlrp3, Pycard, Casp1 and Il1b genes, encoding NLRP3, ASC, caspase 1 and IL-1β, respectively,
showed a prevalent expression in microglial cells (S1A Fig.).
Next, we studied temporal changes of NLRP3 inflammasome-related transcripts in the brain
during prion disease development. To this aim, we interrogated the prion disease database,
which includes microarray-based gene expression data in mouse models of prion disease
[25,26]. We analysed different time points during prion disease and different combinations of
both mouse and prion strains [25,26]. We found that these transcripts are either unchanged
(Nlrp3 and Il1b) or only moderately upregulated (Pycard and, to a less extent, Casp1) in the latest
stages of prion disease with respect to baseline levels (S1B Fig.). These changes were modest in
comparison to other microglia specific transcripts, as Cd68 (S1B Fig.). Overall these data indicate
that NLRP3 inflammasome-related transcripts are only marginally affected during prion disease.
NLRP3 and prion pathogenesis
To investigate the role of NLRP3 in prion pathogenesis, we elected to use NLRP3-deficient
(Nlrp3-/-) mice [27]. We first verified that genetic ablation of NLRP3 did not significantly influ-
ence PrPC levels. Sandwich ELISA on brain homogenates from Nlrp3-/- and C57BL/6 wild-type
mice excluded such an effect (S2 Fig.). We then injected intracerebrally (i.c.) Nlrp3-/- and
C57BL/6 wild-type mice with mouse-adapted scrapie prions (Rocky Mountain Laboratory
strain, passage #6; RML6) [31]. Nlrp3-/- and C57BL/6 wild-type mice displayed similar survival
times after inoculation with two different doses of RML6 prions (Fig. 1A-B; 90 ng = median
survival Nlrp3-/- 182 dpi, C57BL/6 181 dpi; P = 0.79, log-rank test; 30 ng = Nlrp3-/- 211 dpi,
C57BL/6 206 dpi; P = 0.21, log-rank test). Both genotypes showed histologic features typical of
prion disease, including spongiosis, micro- and astrogliosis as well as accumulation of partially
PK-resistant PrP in brains as assessed by Western blotting (Fig. 1C-D). Conversely, upon i.c.
injection of 90 ng of non-infectious brain homogenate, Nlrp3-/- mice survived more than 450
days in the absence of clinical signs of prion disease (S3 Fig.). We next asked whether NLRP3
genetic ablation would have an impact on the production of IL-1β in brains of prion-infected
mice. We measured IL-1β levels in brains of terminally sick mice that received 30 ng of RML6
i.c. by sandwich ELISA. We saw no significant difference in IL-1β levels between Nlrp3-/- and
C57BL/6 control brains (Fig. 1E). Brain IL-1β levels also did not differ between terminally sick
NLRP3/ASC Inflammasomes in Prion Disease
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Fig 1. Prion disease in the absence of NLRP3. A-B Kaplan-Meier survival plots ofNlrp3-/- (blue line) and C57BL/6 wild-type mice (black line) inoculated
intracerebrally with 90 ng (A) or 30 ng of RML6 (B). For each experimental group, the number of mice is indicated (n). Censored events (ticks) indicate
intercurrent deaths not related with prion disease. With both doses, no statistically significant difference was observed (90 ng = median survival Nlrp3-/- 182
dpi, C57BL/6 181 dpi, P = 0.79; 30 ng = Nlrp3-/- 211 dpi, C57BL/6 206 dpi, P = 0.21, log-rank test).C Histological analysis of Nlrp3-/- (I-IV) and C57BL/6 wild-
type mice (V-VIII). Representative hematoxylin and eosin staining (H&E) and immunohistochemical stainings for microglia (IBA1), astrocytes (GFAP) and
partially protease-resistant PrP (SAF-84) in cerebellar areas are displayed. Scale bar: 250 µm.DWestern blotting analysis of partially protease K (PK)-
resistant PrP as detected with POM1 in brain homogenates after PK digestion (PK +). Neg Ctrl: brain homogenate from a control mouse not inoculated with
prions is shown with (PK +) and without (PK -) PK digestion. E Levels of IL-1β in brains of terminally sick mice. Each point denotes one mouse. Mean +/-
standard deviation are shown. No significant difference was observed (P = 0.13, Student’s t test). C, D and E are referred to mice inoculated with 30 ng of
RML6.
doi:10.1371/journal.pone.0117208.g001
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C57BL/6 mice and control mice injected with non-infectious brain homogenate (S4 Fig.).
These results exclude a significant effect of NLRP3 genetic ablation on prion occurrence and
incubation as well as on brain IL-1β levels at the terminal stage of the disease.
ASC and prion pathogenesis
To further validate our results, we investigated the effect of genetic ablation of the NLRP3
inflammasome adaptor protein ASC on prion disease using ASC-deficient (Pycard-/-) mice
[28]. Again, genetic ablation of ASC did not alter brain PrPC levels (S2 Fig.). After i.c. inocula-
tion with RML6 prions, both Pycard-/- and C57BL/6 wild-type mice presented similar survivals
(Fig. 2A-B; 90 ng = median survival Pycard -/- 189 dpi, C57BL/6 194 dpi; P = 0.35, log-rank
test; 30 ng = Pycard -/- 187 dpi, C57BL/6 191 dpi; P = 0.23, log-rank test). Both genotypes
showed histologic features characteristic of prion disease, accumulation of partially PK-resis-
tant PrP and similar levels of IL-1β in the brain (Fig. 2 C-E). Pycard-/- mice injected i.c. with 90
ng of normal brain homogenate did not develop any sign of prion disease and survived more
than 450 days post-injection (S3 Fig.).
When using a lower dose of prions (9 ng of RML6 i.c.), Nlrp3-/-, Pycard -/- and C57BL/6
wild-type mice showed an incomplete attack rate (11/16, 8/13, 7/15, respectively), with no sig-
nificant difference in survival among the three genotypes (S3 Fig.). These results rule out a sig-
nificant effect of ASC genetic ablation on prion occurrence and incubation as well as on brain
IL-1β levels at the terminal stage of the disease.
Discussion
Here we have investigated the role of the NLRP3 inflammasome on prion disease in vivo. Ge-
netic ablation of NLRP3 did not exert any significant impact on prion pathogenesis upon i.c.
inoculation with different doses of RML6 prions. NLRP3-deficient mice showed similar incu-
bation times compared to wild-type controls and displayed biochemical and neuropathological
features characteristic of prion diseases. These data exclude a significant role for NLRP3
inflammasome in our model.
Similar results were obtained with mice lacking the adaptor protein ASC, confirming our re-
sults with Nlrp3-/- mice and incontrovertibly ruling out any requirement for several NLRP3-
independent, ASC-dependent inflammasomes, including the AIM2 [33], NLRP6 [34] and
NLRP12 [35] inflammasomes and the non-canonical MALT1-ASC-caspase 8 inflammasome
[36]. Also, even if NLRP1 and NLRC4 can induce caspase-1 activation and IL-1β production
independently of ASC, it has been shown that ASC is required for the optimal activation of
NLRP1 [37] and NLRC4 [38] inflammasomes.
The IL-1β response to prions is the subject of controversies. Increased levels of IL-1β have
been reported in the cerebrospinal fluid of patients affected by Creutzfeldt-Jakob disease [39,40],
as well as in the brain of mice or hamsters inoculated with rodent-adapted scrapie prions
[41–43]. However, other reports failed to confirm these observations [44,45]. The source of this
increase in IL-1β during prion diseases has not been elucidated. Recently, Heneka and coworkers
reported that genetic ablation of NLRP3 resulted in a significant reduction of total IL-1β levels in
brains of transgenic mice overexpressing human amyloid β (APPPS1NLRP3-/- vs APPPS1),
whereas brain levels of IL-1β were not different between wild-type andNLRP3-/- mice [17].
This controversial state of affairs motivated us to investigate the contribution of NLRP3/
ASC inflammasomes to brain levels of IL-1β in our experimental model of prion disease. We
found no significant difference in total IL-1β levels in brains of terminally sick mice inoculated
with RML6 prions as compared to brains of mice injected with non-infectious brain homoge-
nate. Also, contrary to what might have been predicted from the findings discussed above, we
NLRP3/ASC Inflammasomes in Prion Disease
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Fig 2. Prion disease in the absence of ASC. A-B Kaplan-Meier survival plots of Pycard-/- (red line) and C57BL/6 wild-type mice (black line) inoculated
intracerebrally with 90 ng (A) or 30 ng of RML6 prions (B). For each experimental group, the number of mice is indicated (n). With both doses, no statistically
significant difference was observed (90 ng = median survival Pycard -/- 189 dpi, C57BL/6 194 dpi, P = 0.35; 30 ng = Pycard -/- 187 dpi, C57BL/6 191 dpi, P =
0.23, log-rank test). C Histological analysis of Pycard-/- (I-IV) and C57BL/6 wild-type mice (V-VIII). Representative hematoxylin and eosin staining (H&E) and
immunohistochemical stainings for microglia (IBA1), astrocytes (GFAP) and partially protease-resistant PrP (SAF-84) in cerebellar areas are displayed.
Scale bar: 250 µm. DWestern blotting analysis of partially protease K (PK)-resistant PrP as detected with POM1 in brain homogenates after PK digestion
(PK +). Neg Ctrl: brain homogenate from a control mouse not inoculated with prions is shown with (PK +) and without (PK -) PK digestion. E Levels of IL-1β in
brains of terminally sick mice. Each point denotes one mouse. Mean +/- standard deviation are shown. No significant difference was observed (P = 0.28,
Student’s t test). C, D and E are referred to mice inoculated with 30 ng of RML6.
doi:10.1371/journal.pone.0117208.g002
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found that genetic ablation of NLRP3 or ASC did not significantly alter the brain levels of IL-
1β at the terminal stage of the disease. This result does not necessarily contradict previous stud-
ies showing the importance of NLRP3/ASC inflammasomes for IL-1β production [13–-
15,18,46], in vitro and in vivo, in light of the existence of alternative mechanisms leading to IL-
1β secretion independently of NLRP3/ASC inflammasomes. These mechanisms can rely on
other NOD-like receptor, like NOD1 [47] or on extracellular proteases, including proteinase 3
[48,49], matrix metalloproteinases [50], mast cell chymase [51] and others. In particular, sever-
al IL-1β-mediated phenotypes have been reported to be unaltered in the absence of caspase-1,
underscoring the relevance of additional sources of IL-1β independent of NLRP3/ASC inflam-
masomes [52,53]. It is possible that some of these mechanisms may be of relevance to prion
pathogenesis. Interestingly, several studies showed an upregulation of IL-1β transcripts in
mouse scrapie [54–57], in naturally-occurring scrapie of sheep [58] and in human Creutzfeldt-
Jakob disease cases [59,60]. Collectively, these data indicate that transcriptional mechanisms
could be of relevance for the release of IL-1β during prion disease. On the other hand, other
studies failed to detect a significant change in IL-1β transcripts during prion disease develop-
ment [25,26]. Again, the origin of these discrepancies has yet to be established.
Mice lacking the IL-1 type 1 receptor (IL-1R1) were reported to have an increased survival
compared to wild-type controls after prion inoculation [57,61], but it remained unclear wheth-
er this effect was due to the lack of IL-1β signaling through the IL-1R1 receptor. IL-1α is consti-
tutively expressed by a variety of cells, including astrocytes within the CNS, also binds IL-1R1,
and it has biological properties similar to IL-1β [46]. The role of IL-1α in prion pathogenesis is
presently unknown.
The NLRP3 inflammasome was claimed to be crucially implicated in the release of IL-1β
upon exposure to the amyloidogenic peptide PrP106–126 [21,22] and to recombinant PrP fibrils
[23], at least in vitro. This process was dependent on phagocytosis of PrP-derived moieties and
subsequent lysosomal destabilization [23,62], reminiscent of the mechanism underlying
NLRP3 inflammasome-dependent release of IL-1β caused by amyloid β [16,17]. Based on these
studies, it was postulated that pharmacological interference with the NLRP3 inflammasome/
IL-1β signaling pathway could be beneficial against prion diseases [21,23,62]. However, in our
study the genetic ablation of NLRP3 or ASC did not ameliorate the course of the disease. There
have been previous examples of incongruences between promising in vitro studies reporting
activation of NLRP3 inflammasome by a specific pathogen and disappointing in vivo investiga-
tions of the same pathogen, for example forMycobacterium tuberculosis [63,64]. These discrep-
ancies can reflect the more complex situation of in vivo vs. in vitro experimental paradigms. In
the case of prion disorders, all previous studies suggesting a role for the NLRP3 inflammasomes
were conducted with the PrP106–126 neurotoxic peptides or in vitro generated PrP aggregates or
fibrils which, unlike bona fide prions, are not infectious and may trigger neurotoxicity by differ-
ent pathways from those activated in prion infections.
In our study, mice lacking NLRP3 or ASC were inoculated with rodent-adapted scrapie pri-
ons of the RML type. However prions exist in many different strains differing for their structur-
al properties and causing disease with specific features when inoculated into genetically
identical hosts [65]. Hafner-Bratkovic et al. reported that the NLRP3 inflammasome was acti-
vated only by PrP fibrils and large aggregates, but not by oligomers and monomers, suggesting
the size of PrP aggregates as an important determinant for this phenomenon [23]. The size of
the most infectious prion particles as well as the dynamics of prion replication and processing
in different cells of the CNS are all strain-dependent properties of the infectious agent [66,67].
Also, microglia activation and brain levels of inflammatory cytokines have been reported to di-
verge in different types of prion diseases, possibly reflecting strain-specific features [68–70].
NLRP3/ASC Inflammasomes in Prion Disease
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Based on these considerations, it is not excluded that an involvement of NLRP3 or ASC may
become more apparent in specific forms of prion diseases different from those studied here.
Be as it may, our study adds to the general consensus that the identification of realistic thera-
peutic targets necessitates robust animal models which recapitulate the salient aspects of the dis-
ease in question. Failure to adhere to the latter has led research astray in a worrisome number of
cases [71]. Once again, we found that a claim of therapeutic efficacy solely based on exposure of
cell lines to an artificial aggregate such as the amyloidogenic peptide PrP106–126, which bears little
resemblance to bona fide prions, can lead to unjustified and essentially incorrect conclusions.
Supporting Information
S1 ARRIVE Checklist. Checklist according to ARRIVE guidelines for Reporting Animal
Research—In vivo experiments.
(PDF)
S1 Fig. NLRP3 inflammasome-related transcripts during prion disease. A Expression levels
of different NLRP3 inflammasome-related transcripts in different cell types of mouse brain
cortex as assessed by RNA-sequencing of acutely purified cell populations. OPC: oligodendro-
cyte precursor cells; FPKM: fragments per kilobase of transcript per million mapped reads.
Based on whole transcriptome profile, it is concluded that OPC cell preparation has 5% of
microglia contamination. Scale bars indicate standard deviation. Data and graphs are from
Zhang et al. J Neurosci 2014 [24]. B Dynamic gene expression profiles during prion disease de-
velopment in four mouse strain! prion strain combinations as obtained by microarray analy-
sis. RML! FVB.129-Prnp0/0 combination serves as control, as these mice lack PrPC and are
resistant to prion infection. Data are from Hwang et al. Mol Systm Biol 2009 [25,26].
(TIF)
S2 Fig. PrPC levels in CNS of mice lacking NLRP3/ASC. A-B Levels of PrPC in forebrain (A)
and cerebellum (B) of Nlrp3-/-, Pycard-/- and C57BL/6 wild-type control mice. Each point de-
notes one mouse. Mean +/- standard deviation are shown. No significant difference was ob-
served (P = 0.24 in A, P = 0.15 in B, One-way ANOVA).
(TIF)
S3 Fig. Brain IL-1β levels in terminally prion infected and control injected mice. Levels of
IL-1β in brains of terminally sick C57BL/6 mice (RML) and control mice injected with non-
infectious brain homogenate (NBH). Mice received 30 µg of RML6 or control homogenate.
Each point denotes one mouse. Mean +/- standard deviation are shown. No significant differ-
ence was observed (P = 0.40, Student’s t test).
(TIF)
S4 Fig. Survival upon intracerebral inoculation with a low dose of prions. Kaplan-Meier sur-
vival plots of Nlrp3-/- (blue line), Pycard-/- (red line) and C57BL/6 wild-type mice (black line)
inoculated intracerebrally with 9 ng of RML6. No statistically significant difference among
prion-inoculated mice was observed (attack rate and median survival: Nlrp3-/-, 11/16, 241 dpi;
Pycard-/- 8/13, 256 dpi; C57BL/6, 7/15, median survival not reached; P = 0.55, log-rank test).
Dashed lines indicate mice injected with 90 ng of non-infectious brain homogenates (NBH).
For each experimental group, the number of mice is indicated (n). Censored events (ticks) indi-
cate intercurrent deaths not related with prion disease or termination of the experiment.
(TIF)
S5 Fig. Uncropped images of Western blots presented in this study. AOriginal image of
Western blot presented in Fig. 1D and the relative image showing molecular size marker in B.
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COriginal image of Western blot presented in Fig. 2D and the relative image showing molecu-
lar size marker inD.
(TIF)
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